SCHEMBL884399

SCHEMBL884399

CCC(=O)N[C@H]1CCCCC1n1c(-c2ccccc2)c(C(=O)N2CCNCC2)n(CCCNC(=O)CC(C)C)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 4/20 0.34
KMT2A Q03164 3/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
HTT P42858 1/20 0.33
TP53 P04637 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
USP19 O94966 3/20 0.32
ADRA1A P35348 1/20 0.32
DRD3 P35462 1/20 0.32
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884552 0.96 ALDH1A1 (0.33) GAAMAPTLMNAPKMALDH1A1
SCHEMBL8178068 0.94 ALDH1A1 (0.33) GAAMAPTLMNAPKMALDH1A1
SCHEMBL884492 0.90 SLC6A2 (0.35) GAAMAPTLMNAPKMALDH1A1
SCHEMBL885654 0.89 TP53 (0.35) GAAMAPTLMNAPKMALDH1A1
SCHEMBL884966 0.89 TP53 (0.35) GAAMAPTLMNAPKMALDH1A1
SCHEMBL2063820 0.88 REN (0.32) GAAMAPTLMNAPKMALDH1A1
SCHEMBL2063305 0.86 MEN1 (0.34) GAAMAPTLMNAPKMALDH1A1
SCHEMBL884196 0.85 CHRM1 (0.36) GAAMAPTALDH1A1KMT2AKDM4E
SCHEMBL2062649 0.85 USP19 (0.32) ALDH1A1USP19
SCHEMBL885527 0.84 USP19 (0.34) ALDH1A1KMT2AHPGDMEN1USP19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US claimed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US claimed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT GAA 96/4885MAPT 2847/4885LMNA 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.